Nephrogenic diabetes insipidus (NDI): Clinical, laboratory and genetic characterization of five Brazilian patients

Clinics

Volumn 64, Issue 5, 2009, Pages 409-414

  Vaisbich, Maria Helena ^a   Carneiro, Juliana ^b   Bóson, Wolfanga ^b   Resende, Bruna ^b   de Marco, Luiz ^b   Honjo, Rachel S ^a   Kim, Chong Ae ^a   Koch, Vera H ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Children; Hydrochlorothiazide; Molecular study; Nephrogenic insipidus diabetes; Pharmacological chaperones

Indexed keywords

VASOPRESSIN RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BODY WEIGHT; BRAZIL; CHILD; FOLLOW UP; GENETICS; HUMAN; MALE; MUTATION; NEPHROGENIC DIABETES INSIPIDUS; PATHOLOGY; PHYSIOLOGY;

ADOLESCENT; BODY HEIGHT; BODY WEIGHT; BRAZIL; CHILD; DIABETES INSIPIDUS, NEPHROGENIC; FOLLOW-UP STUDIES; HUMANS; MALE; MUTATION; RECEPTORS, VASOPRESSIN; YOUNG ADULT;

EID: 67749111419     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322009000500007     Document Type: Article

References (19)

1. Sasaki S. Nephrogenic diabetes insipidus: update of genetic and clinical aspects. Nephrol Dial Transplantation. 2004; 19: 1351-3.
2. Knoers NV, Deen PM. Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr Nephrol. 2001; 16: 1146-52.
3. Bichet DG. Nephrogenic Diabetes Insipidus. Advances in Chronic Kidney Dis. 2006; 13: 96-194.
4. Morello JP, Bichet DG. Nephrogenic Diabetes Insipidus. Annu Rev Physiol. 2001; 63: 607-30.
5. Schrier RW. Body Water Homeostasis: Clinical Disorders of Urinary Dilution and Concentration. JASN 2006; 17: 820-2.
6. Morello JP, Bouvier M, Petäjä-Repo UE, Bichet DG. Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol Sci. 2000; 21: 466-9.
7. van Lieburg AF, Verdijk MA, Schoute F, Ligtenberg MJ, van Oost BA, Waldhauser F, et al. Clinical phenotype of nephrogenic diabetes insipidus in females heterozygous for a vasopressin type 2 receptor mutation. Hum Genet. 1995; 96: 70-8.
8. Seibold A, Brabet P, Rosenthal W, Birnbaumer M. Structure and chromosomal localization of the human antidiuretic hormone receptor gene. Am J Hum Genet. 1992; 51: 1078-83.
9. Boson WL, Della Manna T, Damiani D, Miranda DM, Gadelha MR, Liberman B, et al. Novel vasopressin type 2 (AVPR2) gene mutations in Brazilian nephrogenic diabetes insipidus patients. Gen Test 2006;10: 157-62.
10. Fujiwara TM, Bichet DG. Molecular Biology of Hereditary Diabetes Insipidus. J Am Soc Nephrol. 2005; 16: 2836-46.
11. Sasaki S, Fushimi K, Saito H, Saito F, Uchida S, Ishibashi K, et al. Cloning, characterization, and chromosomal mapping of human aquaporin of collecting duct. J Clin Invest. 1994; 93: 1250-6.
12. Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus MF, Lonergan M, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest. 2000; 105: 887-95.
13. Robben JH, Sze M, Knoers NVAM, Deen PMT. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. Am J Physiol Renal Physiol. 2007; 292: F253-60.
14. Friedman E, Carson E, Larsson C, DeMarco L. A polymorphism in the coding region of the vasopressin type 2 receptor (AVPR2) gene. Hum Mol Genet. 1993; 2: 1746.
15. Lejarraga H, Caletti MG, Caino S, Jimenéz A. Long-term growth of children with nephrogenic diabetes insipidus. Pediatr Nephrol. 2008; 23: 2007-12.
16. Kim GH, Lee JW, Oh YK, Chang HR, Joo KW, Na KY, et al. Antidiuretic Effect of Hydrochlorothiazide in Lithium-Induced Nephrogenic Diabetes Insipidus Is Associated with Upregulation of Aquaporin-2, Na-Cl Co-transporter, and Epithelial Sodium Channel. JASN. 2004; 15: 2836-43.
17. Bennet WM. V2 Receptor antagonists in cystic kidney diseases: an exciting step towards a practical treatment. JASN. 2005; 16: 838-9.
18. Ohmishi A, Orita Y, Takagi N, Fujita T, Toyoki T, Ihara Y, et al. Aquaretic effect of a potent, orally, active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther. 1995; 272: 546-51.
19. Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002; 139: 197-210.